Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

H. Huynh, P.K.H. Chow, N. Palanisamy, Manuel Salto-Tellez, B.C. Goh, C.K. Lee, A. Somani, H.S. Lee, R. Kalpana, K. Yu, P.H. Tan, J. Wu, R. Soong, M.H. Lee, H. Hor, K.C. Soo, H.C. Toh, P. Tan

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background/Aims: Hepatocellular carcinoma is a leading cause of global cancer mortality, with standard chemotherapy being minimally effective in prolonging survival. We investigated if combined targeting of vascular endothelial growth factor protein and expression might affect hepatocellular carcinoma growth and angiogenesis.
Original languageEnglish
Pages (from-to)52-60
Number of pages9
JournalJournal of Hepatology
Volume49
Issue number1
DOIs
Publication statusPublished - Jul 2008

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Huynh, H., Chow, P. K. H., Palanisamy, N., Salto-Tellez, M., Goh, B. C., Lee, C. K., Somani, A., Lee, H. S., Kalpana, R., Yu, K., Tan, P. H., Wu, J., Soong, R., Lee, M. H., Hor, H., Soo, K. C., Toh, H. C., & Tan, P. (2008). Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Journal of Hepatology, 49(1), 52-60. https://doi.org/10.1016/j.jhep.2008.02.022